A unique monoclonal protein, Pritoxaximab – formerly known as DXX00601 – shows remarkable promise within the treatment of severe hemolytic reaction (TRALI). Developed by the company, Pritoxaximab works by https://www.targetmol.com/compound/pritoxaximab